UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights March 16, 2021 Evaluated initial observations in CUE-101 Phase 1 monotherapy dose escalation clinical trial for treatment of human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC), which demonstrated tolerability and generated encouraging emerging metrics pertaining to pharmacokinetic and pharmacodynamic profile, as well as early signs of anti-tumor act ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2020 Earnings Conference Call March 16, 2021 4:30 PM ET Company Participants George Zavoico - VP, IR & Corporate Development Daniel Passeri - CEO & Director Kenneth Pienta - Acting Chief Medical Officer Matteo Levisetti - SVP, Clinical Development Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - VP, Finance, Principal Finance & Accounting Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company Reni Benjamin - JMP Securities Kal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) 47-3324577 (I.R. ...

Corporate Presentation Immune Responses, On Cue™ Nasdaq: CUE | November 2020 | O P H A R M A y Forward-Looking Statements Disclaimer This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CUE The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU ...

Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2020 Results Earnings Conference Call August 31, 2020 4:30 PM ET Company Participants George Zavoico - Vice President, Investor Relations & Corporate Development Dan Passeri - President and Chief Executive Officer Anish Suri - Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Kerri-Ann Millar - VP of Finance and Principal Accounting and Finance Officer Conference Call Participants Stephen Willey - Stifel Madhu Kumar - Baird Thomas Shrader - BTIG Reni Benj ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3324577 (State or Other Jurisdictio ...

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Dan Passeri Q1 2020 Earnings Conference Call May 19, 2020 4:30 PM ET Company Participants Ashley Robinson - LifeSci Advisors Dan Passeri - President and Chief Executive Officer Anish Suri - Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Kerri-Ann Millar - VP of Finance and Principal Accounting and Finance Officer Conference Call Participants Boris Peaker - Cowen Stephen Willey - Stifel Mark Breidenbach - Oppenheimer Madhu Kumar - Robert W. Baird Reni ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38327 Cue Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3324577 (State or Other Jurisdicti ...